Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 6/20 | 0.43 |
| ▸ | JAK3 | P52333 | 6/20 | 0.43 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.43 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.42 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13928212 | 0.89 | AURKA (0.42) | JAK2JAK3NPC1 | |
| SCHEMBL3249792 | 0.88 | NPC1 (0.40) | SPHK1SYKJAK2JAK3NPC1 | |
| SCHEMBL3242013 | 0.88 | PDPK1 (0.43) | JAK2JAK3NPC1 | |
| SCHEMBL3244486 | 0.88 | CAMK2D (0.51) | SPHK1SYKJAK2JAK3CAMK2D | |
| SCHEMBL3254744 | 0.87 | JAK2 (0.44) | SPHK1SYKJAK2JAK3CAMK2D | |
| Formic Acid SCHEMBL3249548 | 0.86 | JAK3 (0.40) | JAK2JAK3NPC1 | |
| SCHEMBL3253182 | 0.84 | JAK2 (0.43) | JAK2JAK3NPC1CDC7 | |
| SCHEMBL3253176 | 0.84 | MEN1 (0.44) | JAK2JAK3NPC1ALOX5GSK3B | |
| SCHEMBL3247681 | 0.83 | JAK2 (0.42) | JAK2JAK3NPC1 | |
| SCHEMBL3252757 | 0.81 | NPC1 (0.51) | JAK2JAK3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899335-B1 | PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PF MEDICAMENT (FR) | 2010-05-19 | — | — | EP | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | SPHK1 677/4885SYK 448/4885JAK2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.